JP2021515544A5 - - Google Patents
Info
- Publication number
- JP2021515544A5 JP2021515544A5 JP2020543213A JP2020543213A JP2021515544A5 JP 2021515544 A5 JP2021515544 A5 JP 2021515544A5 JP 2020543213 A JP2020543213 A JP 2020543213A JP 2020543213 A JP2020543213 A JP 2020543213A JP 2021515544 A5 JP2021515544 A5 JP 2021515544A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- antigen
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1804094.9 | 2018-03-14 | ||
| GBGB1804094.9A GB201804094D0 (en) | 2018-03-14 | 2018-03-14 | ERBB3 Binding agents |
| PCT/EP2019/056506 WO2019175359A1 (en) | 2018-03-14 | 2019-03-14 | De-immunised anti-erbb3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515544A JP2021515544A (ja) | 2021-06-24 |
| JP2021515544A5 true JP2021515544A5 (enExample) | 2022-05-26 |
Family
ID=61972871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543213A Pending JP2021515544A (ja) | 2018-03-14 | 2019-03-14 | Ｅｒｂｂ３結合剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10975165B2 (enExample) |
| EP (1) | EP3765156A1 (enExample) |
| JP (1) | JP2021515544A (enExample) |
| CN (1) | CN111818972A (enExample) |
| AU (1) | AU2019233694A1 (enExample) |
| CA (1) | CA3092610A1 (enExample) |
| GB (1) | GB201804094D0 (enExample) |
| SG (1) | SG11202008513WA (enExample) |
| WO (1) | WO2019175359A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301269A (en) | 2020-09-14 | 2023-05-01 | Ichnos Sciences S A | Antibodies that bind to IL1RAP and their uses |
| CN115843256B (zh) * | 2020-10-15 | 2026-03-06 | 上海翰森生物医药科技有限公司 | 抗erbb3抗体或其抗原结合片段及其医药用途 |
| WO2023198138A1 (zh) * | 2022-04-13 | 2023-10-19 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
| TW202432185A (zh) * | 2022-10-28 | 2024-08-16 | 美商翰森生物有限責任公司 | 配體－細胞毒性藥物綴合物及其藥物用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201200195A1 (ru) * | 2009-08-21 | 2012-12-28 | Мерримаск Фармасьютикалс, Инк. | АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ |
| MX343227B (es) * | 2010-04-09 | 2016-10-28 | Aveo Pharmaceuticals Inc | Anticuerpos anti-erbb3. |
| CA2813796C (en) * | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
| US8476409B2 (en) * | 2011-04-19 | 2013-07-02 | Merrimack Pharmaceuticals, Inc. | Bispecific anti-IGF-1R and anti-ErbB3 antibodies |
| WO2013164689A2 (en) * | 2012-05-02 | 2013-11-07 | Lantto, Johan | Humanized pan-her antibody compositions |
| US9725520B2 (en) * | 2013-03-14 | 2017-08-08 | The Board Of Regents Of The University Of Texas System | HER3 specific monoclonal antibodies for diagnostic and therapeutic use |
| US10647756B2 (en) * | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
-
2018
- 2018-03-14 GB GBGB1804094.9A patent/GB201804094D0/en not_active Ceased
-
2019
- 2019-03-14 EP EP19711578.5A patent/EP3765156A1/en not_active Withdrawn
- 2019-03-14 CN CN201980017723.3A patent/CN111818972A/zh active Pending
- 2019-03-14 JP JP2020543213A patent/JP2021515544A/ja active Pending
- 2019-03-14 CA CA3092610A patent/CA3092610A1/en active Pending
- 2019-03-14 SG SG11202008513WA patent/SG11202008513WA/en unknown
- 2019-03-14 AU AU2019233694A patent/AU2019233694A1/en not_active Abandoned
- 2019-03-14 WO PCT/EP2019/056506 patent/WO2019175359A1/en not_active Ceased
-
2020
- 2020-07-10 US US16/925,570 patent/US10975165B2/en not_active Expired - Fee Related
-
2021
- 2021-03-02 US US17/189,860 patent/US20210189003A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519100A5 (enExample) | ||
| JP2021513323A5 (enExample) | ||
| JP2021515541A5 (enExample) | ||
| JP2021516537A5 (enExample) | ||
| JP2025000787A5 (enExample) | ||
| JP2021515542A5 (enExample) | ||
| JP2020531048A5 (enExample) | ||
| JP2024513921A5 (enExample) | ||
| RU2020109544A (ru) | Связывающие агенты | |
| JP2021515544A5 (enExample) | ||
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| JP2017149720A5 (enExample) | ||
| JP2022553908A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| CN105384818B (zh) | 抗人Delta like 4单克隆抗体及其应用 | |
| JP2018506961A5 (enExample) | ||
| JP2020504076A5 (enExample) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2023525495A5 (enExample) | ||
| JP2025500971A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2020521504A (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2013520984A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| HRP20250523T1 (hr) | Pd1 i vegfr2 sredstva za dvostruko vezivanje |